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Abstract
Background: Common single-nucleotide polymorphisms (SNPs) in ten chromosomal loci have been shown to
predispose to colorectal cancer (CRC) in genome-wide association studies. A plausible biological mechanism of
CRC susceptibility associated with genetic variation has so far only been proposed for three loci, each pointing to
variants that affect gene expression through distant regulatory elements. In this study, we aimed to gain insight
into the molecular basis of seven low-penetrance CRC loci tagged by rs4779584 at 15q13, rs10795668 at 10p14,
rs3802842 at 11q23, rs4444235 at 14q22, rs9929218 at 16q22, rs10411210 at 19q13, and rs961253 at 20p12.
Methods: Possible somatic gain of the risk allele or loss of the protective allele was studied by analyzing allelic
imbalance in tumour and corresponding normal tissue samples of heterozygous patients. Functional variants were
searched from in silico predicted enhancer elements locating inside the CRC-associating linkage-disequilibrium
regions.
Results: No allelic imbalance targeting the SNPs was observed at any of the seven loci. Altogether, 12 SNPs that
were predicted to disrupt potential transcription factor binding sequences were genotyped in the same
population-based case-control series as the seven tagging SNPs originally. None showed association with CRC.
Conclusions: The results of the allelic imbalance analysis suggest that the seven CRC risk variants are not
somatically selected for in the neoplastic progression. The bioinformatic approach was unable to pinpoint cancer-
causing variants at any of the seven loci. While it is possible that many of the predisposition loci for CRC are
involved in control of gene expression by targeting transcription factor binding sites, also other possibilities, such
as regulatory RNAs, should be considered.
Background
Ten chromosomal loci have thus far been shown to mod-
estly increase colorectal cancer (CRC) risk, based on gen-
ome-wide association studies (GWASs) [1-9]. The tagging
single-nucleotide polymorphisms (SNPs) with the stron-
gest association signal in each locus were rs6983267 at
8q24 [1-3], rs4939827 at 18q21 [4], rs4779584 at 15q13
[5], rs16892766 at 8q23 [6], rs10795668 at 10p14
[6], rs3802842 at 11q23 [7,8], rs4444235 at 14q22 [9],
rs9929218 at 16q22 [9], rs10411210 at 19q13 [9], and
rs961253 at 20p12 [9]. Each of the ten loci independently
predispose to CRC with allelic odds ratios (ORs) of <1.3
and risk allele frequencies range between 7-90% in the
general population [10].
GWASs are based on genotyping SNPs which tag link-
age disequilibrium (LD) blocks in the genome, thus cap-
turing a high proportion of common genetic variation.
Hence, usually the associating tag SNPs are not them-
selves causal but rather are in LD with disease-causing
variants. We have previously demonstrated that the tag
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SNP rs6983267 at 8q24 directly disrupts a TCF-4 tran-
scription factor binding site and enhances Wnt signal-
ling in the colon [11]. This was supported by a
simultaneous study showing a physical interaction
between rs6983267 region and MYC proto-oncogene
[12]. Furthermore, allelic imbalance (AI) at 8q24 seen in
colorectal tumours favors the risk allele G of rs6983267,
suggesting that the locus is somatically selected for in
tumourigenesis [13]. At 18q21, a novel variant that cor-
relates with rs4939827 reduces SMAD7 expression, lead-
ing to aberrant TGFb (transforming growth factor beta)
signalling [14]. Finally, rs16888589 at the 8q23 CRC
locus was shown to influence EIF3 H expression by phy-
sically interacting with the promoter [15]. Unlike at
8q24, no significant difference in the alleles targeted by
imbalance was detected in rs4939827 at 18q21 [4,14]
nor in rs16892766 at 8q23 [15]. It is therefore likely that
many low-penetrance cancer susceptibility loci may be
explained by subtle changes in distant regulatory ele-
ments, and these changes can also play a role in the
somatic tumour development. Based on the genes that
locate inside or near the CRC-associating regions,
including GREM1 at 15q13 and BMP4 at 14q22, altera-
tions in TGFb-superfamily signalling appear to be at the
basis of several loci [10].
Possible biological mechanisms underlying CRC pre-
disposition are yet to be discovered in the seven low-
penetrance loci at 15q13, 10p14, 11q23, 14q22, 16q22,
19q13, and 20p12, which is the focus of this study. First,
possible somatic selection of the risk alleles was evalu-
ated in heterozygous individuals by examining the tag-
ging SNPs in tumour and corresponding normal tissues.
The location of the SNPs at predicted enhancer ele-
ments was then investigated with an in silico tool. As
none of the tagging SNPs were predicted to locate at
transcription factor binding sites, the analysis was
extended to the given LD regions. Putative functional
variants were searched by genotyping all the known
SNPs inside the associating LD regions that were pre-
dicted to disrupt transcription factor binding sites.
Methods
Study population
A population-based series of 1 042 CRC samples col-
lected since 1994 from nine Finnish central hospitals
was used in this study [16,17]. Both germline DNA
extracted from blood or normal colonic tissue and cor-
responding fresh-frozen tumour DNA were available.
Information on histological tumour grade and Duke’s
stage was obtained from pathology reports. The 837
control DNA samples used in this study were anon-
ymous healthy blood donors from the Finnish Red
Cross Blood Transfusion Service. Samples and clinico-
pathologic data were obtained with informed consent
and ethical review board approval in accordance with
the declaration of Helsinki.
Allelic imbalance (AI) analysis
Allelic ratios were compared by sequencing tumour and
respective normal tissue DNA in heterozygous patients, as
described previously [13,18,19]. In brief, allele peak height
ratios of <0.6 and >1.67 between normal and tumour sam-
ples were considered imbalance (Tumour(Allele1/Allele2)/
Normal(Allele1/Allele2)). Tumour and normal samples were
sequenced using Applied Biosystems BigDye v3.1 sequen-
cing chemistry and ABI3730 Automatic DNA sequencer
(Applied Biosystems, Foster City, CA, USA). Peak heights
were manually measured from sequencing chromatograms
using Chromas http://www.technelysium.com.au and
Sequence Scanner (Applied Biosystems) softwares, based
on which the allelic ratio was calculated. First, 90 tumour-
normal pairs were analyzed. If any trend towards imbal-
ance was observed, all the available heterozygote samples
were analyzed. All the tumours were microscopically eval-
uated by a pathologist and at least 64% of the analyzed
tumours contained ≥70% of carcinoma tissue.
Identification of SNPs at transcription factor binding sites
A computational tool called Enhancer Element Locator
(EEL) [20,21], that aligns genomic sequence from two
species and predicts the location of putative transcrip-
tion factor binding sequences and enhancer elements,
was used. In the output, a score is given to each element
based on conservation, clustering, and predicted affinity
of the binding sites. One Mb of human and correspond-
ing mouse sequence surrounding each SNP (500 kb of
flanking sequence up- and downstream) was exported
from the Ensembl database vs 54 http://www.ensembl.
org/index.html. Transcription factor binding-affinity
matrices from the publicly available Jaspar database
http://jaspar.genereg.net/ and those published elsewhere
were used in the alignment [22-24], that was done with
default parameters. All the known SNPs that were pre-
dicted to locate directly at transcription factor binding
sites were selected from enhancers that were inside the
CRC-associating LD regions. We defined LD blocks
using HapMap data http://hapmap.ncbi.nlm.nih.gov/:
chr15: 30 782 050 - 30 841 010 bps (59 kb; human gen-
ome build 36) in rs4779584 [5], chr10: 8 730 000 - 8
810 000 bps (80 kb) in rs10795668 [6], chr11: 110 640
000 - 110 690 000 bps (50 kb) in rs3802842 [8], chr14:
53 477 192 - 53 494 200 bps (17 kb) in rs4444235 [9],
chr16: 67 286 613 - 67 396 803 bps (110 kb)
in rs9929218 [9], chr19: 38 203 614 - 38 300 573 bps
(97 kb) in rs10411210 [9], and chr20: 6 316 089 - 6 354
440 bps (38 kb) in rs961253 [9]. The analysis was
restricted to such SNPs where the EEL score for the
given element was ≥ 300.
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Genotyping of SNPs in cases and controls
Genotyping was carried out using Sequenom MassArray
iPlex Gold (Sequenom, San Diego, CA, USA) performed
by the Institute for Molecular Medicine Finland FIMM
Technology Centre, University of Helsinki. Each 96-well
sample plate contained two negative water controls and
two positive CEPH controls. The concordance between
duplicate controls was 99,79% (479/480 genotypes).
Twelve SNPs (rs11631292, rs62002613, rs17485426,
ENSSNP10169878, rs1999638, rs12273224, rs45615536,
rs10505287, rs57897735 rs10505283, rs2761880, and
rs12893484) were successfully genotyped with MassAr-
ray. Three remaining SNPs (rs28768389, rs12899808,
and rs34812868) were genotyped by direct genomic
sequencing using Applied Biosystems BigDye v3.1
sequencing chemistry and ABI3730 Automatic DNA
sequencer (Applied Biosystems).
Statistical analysis
All the analyses were performed with R software. Exact
binomial test was used in allelic imbalance analysis. Alle-
lic odds ratios, 95% confidence intervals, and P-values
were calculated with Pearson’s Chi-squared test. To
adjust for multiple testing we applied a Bonferroni
correction (not shown in Table 1). Fisher’s exact test was
used in the analysis of clinicopathological characteristics.
Results
The tag SNPs of seven low-penetrance loci were
sequenced in heterozygous tumour-normal pairs, in
order to detect possible AI occurring in the neoplastic
progression. The risk alleles were not significantly tar-
geted by AI in any of the seven SNPs (Table 2). The fre-
quency of overall imbalance (loss of either the risk or
the neutral allele) ranged between 9 and 31% at the
seven loci (Table 2). In rs10411210, ten tumours showed
loss of the neutral allele and five tumours loss of the
risk allele, however AI occurred altogether in only 9% of
the tumours (Table 2). No significant differences were
observed between the two AI groups in terms of Duke’s
stage (P = 0.3) or histological grade (P = 1.0).
The LD regions containing the seven tag SNPs were
further analyzed with EEL. None of the seven tag SNPs
located in predicted transcription factor binding sites.
Thirteen other SNPs in the LD regions located at pre-
dicted binding sites in elements with a score ≥ 300.
Three out of seven loci (16q22, 19q13, and 20p12) con-
tained no SNPs at transcription factor binding sites in
Table 1 Genotyping of 12 SNPS that locate in transcription factor binding sites in low-penetrance CRC loci
Locus SNP bp* SNP ID MAF
controls
MAF
cases
OR 95% CI P Cases (n) Controls (n) Binding
sequence***
TF
15q13 30 782 048 rs4779584** 0.295 0.323 1.14 1.00 -
1.31
0.05 981 1 024
30 806 855 rs28768389 0.088 0.073 1.24 0.97-1.57 0.08 976 837 AAYCAATCACATA GATA2-
FOXL1
30 824 927 rs11631292 0.123 0.108 1.16 0.95-1.42 0.15 1 009 823 YATCC GATA2
30 825 051 rs62002613 monomorphic 1 011 824 KATCT GATA2
30 806 691 rs12899808 monomorphic 976 837 MCAACAT BRCA1
30 804 840 rs34812868 0.431 0.402 1.13 0.99-1.29 0.08 913 821 GTRTCT GATA1
10p14 8 741 225 rs10795668** 0.307 0.271 1.19 1.04-1.37 0.01 951 983
8 743 013 rs17485426 0.129 0.137 1.07 0.88-1.29 0.51 1 010 824 TATMTAAA FOXL1
8 742 714 ENSSNP10169878 0.129 0.137 1.07 0.88-1.29 0.51 1 010 824 CAATCTTAWTTTTT GATA3-
FOXC1
8 783 743 rs1999638 0.123 0.136 1.12 0.92-1.37 0.24 1 010 824 RAATCT GATA3
11q23 110 676
919
rs3802842** 0.239 0.276 1.22 1.06-1.40 0.01 970 994
110 645
918
rs12273224 monomorphic 997 823 TAAATRTA FOXL1
110 669
934
rs45615536 0.01 0.006 1.63 0.77-3.57 0.19 1 009 824 TKGGGG MZF1
14q22 53 480 669 rs4444235** 0.426 0.462 1.16 1.02-1.33 0.03 933 828
53 488 736 rs2761880 0.009 0.008 1.08 0.51-2.23 0.85 1 011 824 GTGTTTYTTTATTCTT FOXJ3
53 484 488 rs12893484 0.384 0.414 1.13 0.99-1.29 0.07 1 010 824 GCCRCAGGC TFAP2A
*Human genome build 36; **Tag SNPs genotyped in previous studies [6,8,9]; ***SNPs indicated as Y = C/T, K = G/T, M = A/C, R = A/G, W = A/T; MAF = minor
allele frequency, TF = transcription factor; rs11631292, rs62002613, rs17485426, ENSSNP10169878, rs1999638, rs12273224, rs45615536, rs10505287, rs57897735
rs10505283, rs2761880, and rs12893484 were genotyped using Sequenom MassArray iPlex Gold; rs28768389, rs12899808, and rs34812868 were genotyped using
genomic sequencing.
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elements with a score ≥ 300. One of the SNPs,
rs11853552 at 15q13, was already previously genotyped
by Jaeger et al. (2008) [5], and was therefore excluded
from the analysis. The remaining 12 SNPs were geno-
typed in the same Finnish case-control series as the tag
SNPs in previous studies (Table 1) [6,8,9]. None of the
SNPs showed association with CRC (Table 1).
Three of the 12 SNPs (rs28768389, rs12899808, and
rs34812868 in 15q13) were genotyped using sequencing
and four additional polymorphisms that did not locate
in any predicted binding sites were observed in the
sequencing fragments. One of these SNPs, rs35614970
(A6/A3), showed significant association with CRC (OR
1.2, 95% CI 1.03-1.38, P = 0.02). The frequency of A6
was 0.705 in controls and 0.741 in cases. This associa-
tion did not remain significant after correction for mul-
tiple testing (P = 0.21, Bonferroni correction for 13
SNPs). None of the other additional SNPs (rs11071928,
rs34944927, and a novel C to T change at chr15: 30 806
922) showed association with CRC.
Discussion
In this study, we exploited the same approach as for
8q24 to systematically analyze molecular basis of seven
low-penetrance CRC loci where the cancer-causing var-
iants have not yet been identified. This is the first time,
to our knowledge, that rs4779584, rs10795668,
rs4444235, rs9929218, rs10411210, and rs961253 have
been analyzed for possible AI in colorectal tumours.
Sequencing of fresh-frozen tumour material provides
accurate data on possible loss of the neutral allele or
gain of the risk allele. In case of selective imbalance,
subsequent copy number analyses can reveal whether
the role of a variant resembles that of a tumour sup-
pressor or an oncogene, and guide further functional
efforts. The 8q24 locus, where gain of the risk allele was
observed in rs6983267 [11,13], currently seems to be the
only low-penetrance risk locus for CRC that is somati-
cally enriched during tumourigenesis. Lack of imbalance
favouring risk allele does not, however, preclude involve-
ment in germline predisposition. It is therefore possible
that some of the seven susceptibility variants analyzed in
this study play a role in the early stages of neoplastic
development, without providing further selective advan-
tage in the somatic cancer progression.
Interestingly, 19q13 gain is common in both primary
and metastatic CRC [25]. We did not, however, observe
any significant difference in the alleles targeted by AI in
rs10411210, nor association of neutral allele loss with
more advanced disease stage. Loss of heterozygosity
involving 10p14 has also been reported to occur in CRC
[26] but we found no evidence of risk allele selection in
rs10795668. Furthermore, deletion of 11q23-q24 is a fre-
quent event in CRC, among other tumour types [27].
However, Tenesa et al. (2008) found no AI in favour of
the risk allele in rs3802842 based on up to 43 CRCs [7],
which is now confirmed by our analysis of 89 CRCs.
Finally, although 18q loss is common in CRC [28],
Broderick et al. (2007) observed no selection of the risk
allele at rs4939827 in 248 CRC cases [4].
The location of rs6983267 at TCF-4 binding sequence
was recently discovered using EEL [11], which prompted
us to utilize this powerful tool also for the seven suscept-
ibility loci. Transcription factor tissue specificities are
incompletely understood, supporting the rationale of our
unbiased approach of not restricting to colon-specific fac-
tors. Given that the tagging SNPs at the seven loci lie in
noncoding regions, the most likely underlying mechanism
is differential gene expression through enhancers or
repressors. Although regulatory SNPs have been identified
in the loci successfully fine-mapped so far, our study
underscores the importance of considering also other
mechanisms. For instance, sequence variation affecting
noncoding regulatory RNAs, many of which have been
linked to cancer-associated pathways, could explain some
of the predisposition loci devoid of coding genes.
Conclusion
While successful in the 8q24 locus, the approach used
in this study was unable to pinpoint causal variants in
the seven low-penetrance CRC loci analyzed. Finding
the underlying functional changes in the GWAS loci is a
Table 2 Results of allelic imbalance analysis in low-penetrance CRC loci
Locus SNP Risk allele Neutral allele Imbalancea Loss neutral Loss risk Pb
15q13 rs4779584 T C 17/87 (20%) 8 9 1
10p14 rs10795668 G A 12/90 (13%) 6 6 1
11q23 rs3802842 C A 9/89 (10%) 4 5 1
14q22 rs4444235 C T 17/90 (19%) 7 10 0.63
16q22 rs9929218 G A 10/90 (11%) 6 4 0.75
19q13 rs10411210 C T 15/174 (9%) 10c 5c 0.30
20p12 rs961253 A C 27/88 (31%) 11 16 0.44
aOverall allelic imbalance per heterozygote tumour-normal pairs analyzed.
bRandom targeting of alleles (exact binomial test).
cDukes A-B/C-D: Loss neutral 7/3, loss risk 2/3.
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challenging, yet important, task in order to fully under-
stand the biology behind common CRC susceptibility.
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